{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:06:48Z","timestamp":1761217608348},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,24]]},"DOI":"10.1097\/qad.0b013e32835edc1d","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T10:49:14Z","timestamp":1358333354000},"page":"1081-1090","source":"Crossref","is-referenced-by-count":27,"title":["An ancestral HIV-2\/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity"],"prefix":"10.1097","volume":"27","author":[{"given":"Pedro","family":"Borrego","sequence":"first","affiliation":[]},{"given":"Rita","family":"Calado","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 M.","family":"Marcelino","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Quintas","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Barroso","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Taveira","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R3-4-20210130","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","article-title":"A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.","volume":"9","author":"Wild","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R4-4-20210130","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.","volume":"91","author":"Wild","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-4-20210130","doi-asserted-by":"crossref","first-page":"10598","DOI":"10.1073\/pnas.1932511100","article-title":"The entry of entry inhibitors: a fusion of science and medicine.","volume":"100","author":"Moore","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-4-20210130","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.1074\/jbc.M609148200","article-title":"HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.","volume":"282","author":"Liu","year":"2007","journal-title":"J Biol Chem"},{"key":"R7-4-20210130","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.2174\/138161210794079218","article-title":"Inhibition of HIV-1 by fusion inhibitors.","volume":"16","author":"Eggink","year":"2010","journal-title":"Curr Pharm Des"},{"key":"R8-4-20210130","doi-asserted-by":"crossref","first-page":"12447","DOI":"10.1128\/JVI.79.19.12447-12454.2005","article-title":"Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.","volume":"79","author":"Mink","year":"2005","journal-title":"J Virol"},{"key":"R9-4-20210130","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1: December 2009.","volume":"17","author":"Johnson","year":"2009","journal-title":"Top HIV Med"},{"key":"R10-4-20210130","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"R11-4-20210130","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-4-20210130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.624","article-title":"The history of antiretrovirals: key discoveries over the past 25 years.","volume":"19","author":"De Clercq","year":"2009","journal-title":"Rev Med Virol"},{"key":"R13-4-20210130","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/cmdc.201000289","article-title":"Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.","volume":"5","author":"Cai","year":"2010","journal-title":"ChemMedChem"},{"key":"R14-4-20210130","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1086\/381707","article-title":"Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.","volume":"189","author":"Eron","year":"2004","journal-title":"J Infect Dis"},{"key":"R15-4-20210130","first-page":"S14","article-title":"In vitro antiviral activity of T-1249, a second generation fusion inhibitor.","volume":"7","author":"Greenberg","year":"2002","journal-title":"Antiviral Ther"},{"key":"R16-4-20210130","first-page":"61","article-title":"Discontinuation of the clinical development of fusion inhibitor T-1249.","volume":"6","author":"Martin-Carbonero","year":"2004","journal-title":"AIDS Rev"},{"key":"R17-4-20210130","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.","volume":"283","author":"He","year":"2008","journal-title":"J Biol Chem"},{"key":"R18-4-20210130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ni0407-329","article-title":"Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1.","volume":"8","author":"Rowland-Jones","year":"2007","journal-title":"Nat Immunol"},{"key":"R19-4-20210130","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1089\/0889222041217392","article-title":"Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification.","volume":"20","author":"Damond","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R20-4-20210130","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1128\/JVI.68.11.7433-7447.1994","article-title":"Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology.","volume":"68","author":"Gao","year":"1994","journal-title":"J Virol"},{"key":"R21-4-20210130","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.tim.2008.09.003","article-title":"HIV-2: the forgotten AIDS virus.","volume":"16","author":"de Silva","year":"2008","journal-title":"Trends Microbiol"},{"key":"R22-4-20210130","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1073\/pnas.0936469100","article-title":"Tracing the origin and history of the HIV-2 epidemic.","volume":"100","author":"Lemey","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-4-20210130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.1996.03530270050031","article-title":"The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention.","volume":"275","author":"Hu","year":"1996","journal-title":"JAMA"},{"key":"R24-4-20210130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","article-title":"Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.","volume":"9","author":"Witvrouw","year":"2004","journal-title":"Antivir Ther"},{"key":"R25-4-20210130","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1128\/AAC.37.5.1037","article-title":"Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.","volume":"37","author":"Hizi","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-4-20210130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/088922204322996590","article-title":"Are fusion inhibitors active against all HIV variants.","volume":"20","author":"Poveda","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R27-4-20210130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3851\/IMP1996","article-title":"Baseline susceptibility of primary human immunodeficiency virus type 2 to entry inhibitors.","volume":"17","author":"Borrego","year":"2012","journal-title":"Antivir Ther"},{"key":"R29-4-20210130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/bioinformatics\/14.9.817","article-title":"MODELTEST: testing the model of DNA substitution.","volume":"14","author":"Posada","year":"1998","journal-title":"Bioinformatics"},{"key":"R30-4-20210130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0022-5193(05)80104-3","article-title":"The general stochastic model of nucleotide substitution.","volume":"142","author":"Rodriguez","year":"1990","journal-title":"J Theor Biol"},{"key":"R31-4-20210130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3","article-title":"Analyzing protein circular dichroism spectra for accurate secondary structures.","volume":"35","author":"Johnson","year":"1999","journal-title":"Proteins"},{"key":"R32-4-20210130","doi-asserted-by":"crossref","first-page":"W668","DOI":"10.1093\/nar\/gkh371","article-title":"DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data.","volume":"32","author":"Whitmore","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"R33-4-20210130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/bioinformatics\/18.1.211","article-title":"DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra.","volume":"18","author":"Lobley","year":"2002","journal-title":"Bioinformatics"},{"key":"R34-4-20210130","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1128\/JCM.44.2.607-611.2006","article-title":"Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins.","volume":"44","author":"Marcelino","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R35-4-20210130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-1-59745-170-3_29","article-title":"Isolation of drug-resistant mutant HIV variants using tissue culture drug selection.","volume":"485","author":"Oliveira","year":"2009","journal-title":"Methods Mol Biol"},{"key":"R36-4-20210130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core structure of gp41 from the HIV envelope glycoprotein.","volume":"89","author":"Chan","year":"1997","journal-title":"Cell"},{"key":"R37-4-20210130","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1073\/pnas.78.6.3824","article-title":"Prediction of protein antigenic determinants from amino acid sequences.","volume":"78","author":"Hopp","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R38-4-20210130","doi-asserted-by":"crossref","first-page":"13697","DOI":"10.1021\/bi9606962","article-title":"HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.","volume":"35","author":"Lawless","year":"1996","journal-title":"Biochemistry"},{"key":"R39-4-20210130","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1073\/pnas.1018360108","article-title":"Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.","volume":"108","author":"Sampah","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R40-4-20210130","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.","volume":"14","author":"Shen","year":"2008","journal-title":"Nat Med"},{"key":"R41-4-20210130","doi-asserted-by":"crossref","first-page":"26941","DOI":"10.1074\/jbc.M109.004416","article-title":"Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.","volume":"284","author":"Eggink","year":"2009","journal-title":"J Biol Chem"},{"key":"R42-4-20210130","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1074\/jbc.M809269200","article-title":"Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.","volume":"284","author":"Champagne","year":"2009","journal-title":"J Biol Chem"},{"key":"R43-4-20210130","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/JVI.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.","volume":"59","author":"Adachi","year":"1986","journal-title":"J Virol"},{"key":"R44-4-20210130","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","article-title":"Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.","volume":"72","author":"Rimsky","year":"1998","journal-title":"J Virol"},{"key":"R45-4-20210130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2148-4-33","article-title":"Reconstruction of ancestral protein sequences and its applications.","volume":"4","author":"Cai","year":"2004","journal-title":"BMC Evol Biol"},{"key":"R46-4-20210130","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1586\/14760584.3.4.S151","article-title":"Immunogen sequence: the fourth tier of AIDS vaccine design.","volume":"3","author":"Mullins","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"R47-4-20210130","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1074\/jbc.M807169200","article-title":"Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.","volume":"284","author":"Izumi","year":"2009","journal-title":"J Biol Chem"},{"key":"R48-4-20210130","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.01211-08","article-title":"SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.","volume":"53","author":"Naito","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R49-4-20210130","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J","article-title":"Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.","volume":"41","author":"Otaka","year":"2002","journal-title":"Angew Chem Int Ed Engl"},{"key":"R51-4-20210130","doi-asserted-by":"crossref","first-page":"12585","DOI":"10.1128\/JVI.01726-08","article-title":"Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.","volume":"82","author":"Takeuchi","year":"2008","journal-title":"J Virol"},{"key":"R52-4-20210130","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R53-4-20210130","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.","volume":"74","author":"Derdeyn","year":"2000","journal-title":"J Virol"},{"key":"R54-4-20210130","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.","volume":"72","author":"Platt","year":"1998","journal-title":"J Virol"},{"key":"R55-4-20210130","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J","article-title":"Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia.","volume":"18","author":"Foley","year":"1965","journal-title":"Cancer"},{"key":"R56-4-20210130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/aid.1987.3.283","article-title":"Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.","volume":"3","author":"Nara","year":"1987","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R57-4-20210130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/332469a0","article-title":"Quantitative infectivity assay for HIV-1 and-2.","volume":"332","author":"Nara","year":"1988","journal-title":"Nature"},{"key":"R58-4-20210130","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1006\/viro.1993.1331","article-title":"A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes.","volume":"194","author":"Ghosh","year":"1993","journal-title":"Virology"},{"key":"R59-4-20210130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.gt.3300895","article-title":"Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.","volume":"6","author":"Chang","year":"1999","journal-title":"Gene Ther"},{"key":"R60-4-20210130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1.","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"R61-4-20210130","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.38.4.668","article-title":"Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.","volume":"38","author":"De Clercq","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R62-4-20210130","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/jm00002a019","article-title":"Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.","volume":"38","author":"Bridger","year":"1995","journal-title":"J Med Chem"},{"key":"R63-4-20210130","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1128\/AAC.44.6.1667-1673.2000","article-title":"Pharmacokinetics and safety of AMD-3100: a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.","volume":"44","author":"Hendrix","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R64-4-20210130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/viro.1995.1556","article-title":"Both virus and host components are important for the manifestation of a Nef- phenotype in HIV-1 and HIV-2.","volume":"213","author":"Ryan-Graham","year":"1995","journal-title":"Virology"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-201304240-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T19:36:23Z","timestamp":1714851383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201304240-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,24]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32835edc1d","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,24]]}}}